AJTMH ASTMH Job Mart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 81(3), 2009, pp. 387-389
Copyright © 2009 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Soto, J.
Right arrow Articles by Berman, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soto, J.
Right arrow Articles by Berman, J.

SHORT REPORT


Efficacy of Extended (Six Weeks) Treatment with Miltefosine for Mucosal Leishmaniasis in Bolivia

Jaime Soto*, Jaime Rea, Margarita Valderrama, Julia Toledo, Luis Valda, Jaime Ardiles, AND Jonathan Berman
Centro de Investigaciones Bioclínicas de la Fundación FADER, Bogotá, Colombia; Proyecto Obras Sociales de Caminos de Acceso Rur, Palos Blancos, Bolivia; Departamento Médico, Hospital de Clínicas, La Paz, Bolivia; Servicio de Otorrinolaringología, Hospital de Clínicas, La Paz; Fast-Track Drugs and Biologics LLC, North Potomac, Maryland

 

ABSTRACT

We investigated whether increasing the period of follow-up or increasing the duration of therapy would markedly alter the 71% cure rate of mucosal leishmaniasis in Bolivia consequent to treatment with miltefosine for 4 weeks. Increasing the follow-up from 12 months to 24 months demonstrated additional relapse in only 2 of 41 patients. Increasing the period of therapy from 4 weeks to 6 weeks only increased the cure rate to 75%. The cure rate of mucosal leishmaniasis in Bolivia, whether 4 or 6 weeks of therapy is used and whether 12 month or 24 months follow up is conducted, is approximately 70%.

Received February 2, 2009. Accepted for publication May 28, 2009.

Disclosure: Jonathan Berman serves as a paid consultant to Paladin, manufacturers of miltefosine. This statement is made in the interest of full disclosure and not because the authors consider this a conflict of interest.

* Address correspondence to Jaime Soto, Centro de Investigaciones Bioclínicas de la Fundación FADER, Calle 60 A No. 5-54, Office 201, Bogotá, Colombia. E-mail: jaime.soto{at}prodderma.com

Authors’ addresses: Jaime Soto and Julia Toledo, Centro de Investigaciones Bioclínicas de la Fundación FADER, Calle 60 A No. 5-54, Office 201, Bogotá, Colombia, E-mail: jaime.soto{at}prodderma.com. Jaime Rea and Margarita Valderrama, Proyecto Proyecto Obras Sociales de Caminos de Acceso Rur, Campamento 1 Palos Blancos, Palos Blancos, Bolivia, E-mail: reabalderrama{at}hotmail.com. Luis Valda, Departamento Médico, Hospital de Clínicas, Sector Miraflores La Paz, Bolivia, E-mail: valdarod{at}entelnet.com.bo. Jaime Ardiles, Servicio de Otorrinolaringología, Hospital de Clínicas, Sector Miraflores, La Paz, Bolivia. Jonathan Berman, Fast-Track Drugs and Biologics LLC, 6205 Poindexter Lane, North Bethesda, North Potomac, MD 20852, E-mail: JBerman{at}fasttrackresearch.com.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Society of Tropical Medicine and Hygiene.